Effects of low dose colchicine in patients of CAD undergoing PCI

PGIMER0 个研究点目标入组 180 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•1.Those who give consent for participation in study.
•2.Age >18 years and<85 years
•3. Proven coronary disease; as evidenced by coronary angiography, CT angiography or a
•Coronary Artery Calcium Score > 400 Agatston Units.
•4. Individuals with a history of coronary artery bypass surgery are only eligible if they
•had undergone bypass surgery more than 10 years before or have angiographic evidence
•of graft failure or have undergone coronary intervention since their bypass surgery
•5.Newly diagnosed ACS (UA,STEMI,NSTEMI) undergoing PCI
•6. Patient undergone PTCA within a month

•1.Patients not willing for follow up.
•2. Patients who are refusing to give informed consent
•3. Patients <18 years of age
•4.Women who are pregnant, breastfeeding or may be considering pregnancy during the
•study period
•5.Patients with renal impairment: serum creatinine >1.5mg/dl or eGFR <45mL/min or on
•6. Patients with heart failure with NYHA Class 3 or 4
•7. Patients with valvular heart disease considered likely to require intervention
•8. Patients who is dependent or frail or have a life expectancy < 6 months
•9. Patients with peripheral neuritis, myositis or marked myosensitivity to statins
•10. Patients who already taking long-term colchicine therapy for any other reason
•11.Stroke within the last 3 months
•12.Coronary artery bypass surgery within the last 3 years
•13.Cancer within the last 3 years
•14. Patients with known history of inflammatory bowel disease or chronic diarrhea, cirrhosis,
•drug abuse, or sensitivity to colchicine
•15.Hematological malignancy, thrombocytopenia, leucopenia
•16. Use of oral steroids

发起方